FOLH1 and renal cell carcinoma: Additional prospective studies with integrated tissue, blood, imaging, and clinical correlative analyses will be critical in defining the role of PSMA-based therapeutic strategies such as radioligand therapy in RCC and their impact on future directions for combination therapy strategies involving bispecific antibodies and antibody–drug conjugates.